The CureVac COVID-19 vaccine (abbreviated CVnCoV) was a COVID-19 vaccine candidate developed by CureVac N.V. and the Coalition for Epidemic Preparedness...

German vaccine for protection against COVID-19, caused by infection with the SARS-CoV-2 virus. Clinical trials for the CureVac COVID-19 Vaccine (CVnCoV)...

A COVID‑19 vaccine is a vaccine intended to provide acquired immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus...

review of CureVac's COVID-19 vaccine (CVnCoV)". European Medicines Agency (EMA) (Press release). 1 December 2020. Retrieved 12 February 2021. "CureVac seeks...

an outbreak and hasten the development of a preventive COVID-19 vaccine. Since 2020, vaccine development has been expedited via unprecedented collaboration...

53 billion COVID-19 vaccine doses have been administered worldwide, with 70.6 percent of the global population having received at least one dose. While 4.19 million...

strains (variants) with varying degrees of infectivity and virulence. COVID-19 vaccines were widely deployed in various countries beginning in December 2020...

isothermal amplification (RT‑LAMP) from a nasopharyngeal swab. Several COVID-19 vaccines have been approved and distributed in various countries, many of which...

ingår EU-gemensamt avtal om covid-19-vaccin med CureVac" [Sweden joins the collective EU COVID-19 vaccine contract with CureVac] (Press release) (in Swedish)...

and CureVac on February 21, 2021. Iceland's first doses of vaccine were received on December 28, 2020; vaccination began on December 29. Vaccines were...